辽宁11选5走势图预测|辽宁11选5开奖直播
 
-
Important news
-
News
-
Shenzhen
-
China
-
World
-
Opinion
-
Sports
-
Kaleidoscope
-
Photo Highlights
-
Business
-
Markets
-
Business/Markets
-
World Economy
-
Speak Shenzhen
-
Leisure Highlights
-
Culture
-
Travel
-
Entertainment
-
Digital Paper
-
In depth
-
Weekend
-
Lifestyle
-
Diversions
-
Movies
-
Hotels
-
Special Report
-
Yes Teens
-
News Picks
-
Tech and Science
-
Glamour
-
Campus
-
Budding Writers
-
Fun
-
Futian Today
-
Advertorial
-
CHTF Special
-
FOCUS
-
Guide
-
Nanshan
-
Hit Bravo
-
People
-
Person of the week
-
Majors Forum
-
Shopping
-
Investment
-
Tech and Vogue
-
Junior Journalist Program
-
Currency Focus
-
Food Drink
-
Restaurants
-
Yearend Review
-
QINGDAO TODAY
在線翻譯:
szdaily -> China -> 
New lung cancer medicine under trial
    2019-04-11  08:53    Shenzhen Daily

A DOMESTICALLY developed drug targeting one type of lung cancer is expected to complete clinical trials before the end of year and then receive approval for use among patients soon afterward, say experts from Shanghai Chest Hospital, which is leading the trials.

So far there are no drugs specifically targeting patients with MET exon 14 skipping mutation. This mutation is found in 3 percent of lung cancer patients.

“Both Chinese and Western medical experts are conducting research targeting this mutation and our clinical trial of the new targeted medicine has received considerable attention from the international medical community,” said Dr. Lu Shun from Shanghai Chest Hospital. Lu is also leading research on the drug with assistance from 33 other hospitals in China.

“Current clinical trials saw positive responses in 55 percent of patients, whose average survival is expected to prolong from eight months to over two years,” he said. “The medicine has been included in the ‘green channel’ for innovative drugs for a quicker reviewing and approval process. After being approved, it will become the first medicine in the world targeting such mutations and bring hope to patients who usually have a poor response to chemotherapy and short survival.”

In addition to enhancing new drug development, the domestic medical community has also started to regulate the use of anti-cancer medicines.

“A nationwide training has been carried out this year and the National Health Commission will conduct a wide inspection next year,” said Lu, who is a member of the specialist team on the new guideline.

(Shanghai Daily)

深圳報業集團版權所有, 未經授權禁止復制; Copyright 2010, All Rights Reserved.
Shenzhen Daily E-mail:[email protected]

辽宁11选5走势图预测 大盘股票指数 股票怎么赢利 短线股票推荐,公众号 股票代码查询一览表股票行情中国所有股票代码 金桥大通 金勺子配资 甘孜股票配资 全球股市指数 圣农发展股票资金流 股票配资论坛c互利计划